Breaking News: Pressure BioSciences Names the Vogel Laboratory at New York University's Center for Genomics and Systems Biology a Center of Excellence | Financial Buzz

Breaking News: Pressure BioSciences Names the Vogel Laboratory at New York University’s Center for Genomics and Systems Biology a Center of Excellence

Collaboration with Dr. Christine Vogel and Colleagues in NYU’s Internationally Recognized “Hub of Science” Center Will Provide Scientists Immediate Access to PBI’s Innovative and Proprietary Pressure-Based Platform Technologies

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries, today announced the establishment of a Center of Excellence (“CoE”) at Dr. Christine Vogel’s laboratory at New York University (“NYU”)’s Center for Genomics and Systems Biology (the “GSB Center”).

As a Center of Excellence, the Vogel Lab will have free use of the Company’s primary instrument system, the Barocycler 2320EXTREME (the “2320EXT”) until the end of 2020. They will also be offered early access to new, modified, and/or improved versions of the 2320EXT instrument and its associated applications during the collaboration period. Finally, they will have the opportunity to work closely with PBI’s senior science and engineering staff on new developments in the Company’s pressure-based technology platforms.

Dr. Christine Vogel, an Associate Professor and internationally recognized scientist with multiple publications and awards, is an expert in the field of proteomics (the study of proteins), with special emphasis on protein expression patterns and their relationship to human disease – such as cancer. Dr. Vogel’s laboratory uses state-of-the-art equipment and methods to investigate these and other important properties of proteins, and their association with human disease. As part of the CoE, Dr. Vogel and colleagues, along with students and visitors to the GSB Center, will use PBI’s patented pressure cycling technology™ (“PCT”) platform to help in the development and validation of protocols for tissue-based protein studies that might eventually be used in a clinical setting. In addition, the Vogel laboratory will be open by invitation to local, national, and international scientists for workshops and seminars on the use of the PCT platform in the discovery, identification, and elucidation of proteins that may be involved in human disease.

Ms. Roxana McCloskey, PBI’s Global Director of Sales and Marketing, said: “The innovative 2320EXT intrument is based on PBI’s patented and enabling PCT platform. The 2320EXT is currently used by research scientists worldwide for the safe, rapid, and reproducible lysis of cells and tissues, to release proteins and other important biomolecules (e.g., DNA, RNA, lipids) for analysis. Such analyses are a critical step in the discovery and development of diagnostic, prognostic, and predictive clinical tests used to identify risk, disease presence, or disease progression, and to guide treatment in many diseases, such as cancer.”

Professor Vogel commented: “My laboratory uses the most advanced technologies available to investigate the regulation of proteins in different systems in response to environmental stress. We continually look for powerful, cutting-edge tools to help us reach the highest level of quality possible in our research.”

Dr. Bradford A. Young, Chief Commercial Officer of PBI, said: “We are pleased to have the opportunity to collaborate with Professor Christine Vogel, a well-respected thought leader in proteomics. We believe the 2320EXT has the potential to support and advance the exciting work that she and her team already have underway at the GSB Center. We further believe that the added exposure received by the PCT platform during the collaboration period will increase awareness of the benefits of our pressure-based technologies in helping to provide scientists with superior proteomic analyses. We believe this added awareness should result in increased products and services revenue in 2019 and beyond.”

About the NYU Center for Genomics and Systems Biology

The NYU Center for Genomics and Systems Biology is considered by many as a “hub of science” in New York City. It has state-of-the-art “loft laboratories” where scientists including professors, researchers, and students interact to leverage the extraordinary potential of genomics and systems biology in research and education. This involves the combined skills of genomic, computational, and evolutionary biologists. Faculty also collaborate with researchers in other departments and schools at NYU, such as Physics, Chemistry, Medicine, Engineering, and Global Public Health, as well as with researchers from other major institutions in New York and around the world. The intellectual synergisms brought about by these internal and external collaborations, enable us to develop unique approaches to genomics and systems biology. Working with organisms from all the major branches of the tree of life, researchers at the Center address how genomes encode regulatory genetic networks, respond to changes in the environment or during development, how genes evolve, and how this generates diversity within and across species. These principles are being applied to global questions in human health, food sustainability, bio-energy, and the environment.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, we are actively expanding the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired protein disaggregation and refolding technology from BaroFold, Inc. to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (UST™) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, please visit:

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pressure biosciences, inc, financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. has signed a one-year agreement with pressure biosciences inc. for fifty thousand restricted common shares for continued financial and corporate news dissemination. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: